株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

糖尿病治療薬の世界市場:2017-2027年

Global Diabetes Drugs Market 2017-2027: Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others

発行 Visiongain Ltd 商品コード 269884
出版日 ページ情報 英文 262 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=156.30円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
糖尿病治療薬の世界市場:2017-2027年 Global Diabetes Drugs Market 2017-2027: Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others
出版日: 2017年07月27日 ページ情報: 英文 262 Pages
概要

当レポートでは、世界の糖尿病治療薬の市場について調査し、糖尿病および糖尿病治療の現状、主要薬剤区分および主要薬剤別の主要動向、市場収益の過去の推移と予測、主要国における動向、R&Dの動向、専門家へのインタビューなどをまとめています。

第1章 レポートの概要

第2章 世界の糖糖尿病治療薬市場:イントロダクション

  • 市場区分
  • 糖尿病とは
  • 糖尿病の分類法
  • リスクファクター・症状・合併症
  • 糖尿病の診断基準
  • 世界・地域別の有病率・罹患率
  • 糖尿病における経済負担
  • アンメットニーズ
  • 主要薬剤クラス

第3章 世界の糖尿病治療薬市場の予測

  • 世界の糖尿病治療薬市場の実績
    • 薬剤クラス別
    • 売れ筋糖尿病治療薬
    • ジェネリック抗糖尿病薬
  • 世界の糖尿病治療薬市場:収益予測
  • 注射用糖尿病薬および非注射用糖尿病薬

第4章 ヒトインスリンおよび類似体市場の予測

  • 市場実績
  • 収益予測
  • 市場動向
  • Lantus (インスリンアスパルト - Novo Nordisk)
  • NovoLog (インスリンアスパルト - Novo Nordisk)
  • Humalog (インスリンリスプロ - Eli Lilly)
  • Levemir (インスリンデテミル - Novo Nordisk)
  • Human Insulins (Novo Nordisk)
  • NovoMix (インスリンアスパルト - Novo Nordisk)
  • Humulin (インスリンイソフェン - Eli Lilly)

第5章 DPP-4阻害剤薬市場

  • 市場実績
  • 収益予測
  • Januvia (シタグリプチン - Merck (MSD))
  • Janumet (シタグリプチン&メトホルミン - Merck & Co.)
  • Galvus (ビルダグリプチン - Novartis)
  • Onglyza (サクサグリプチン - AstraZeneca)
  • Nesina (アログリプチン - 武田薬品工業/Furiex Pharmaceuticals)
  • Tradjenta (リナグリプチン - Eli Lilly, Boehringer Ingelheim)

第6章 スルホニル尿素市場

  • 市場実績
  • 収益予測
  • 市場動向
  • Diamicron (グリクラジド - Servier)
  • Amaryl (グリメピリド - Sanofi)
  • Glucotrol XL (グリクラジド - Pfizer)

第7章 GLP-1受容体作動薬市場

  • 市場実績
  • 収益予測
  • Victoza (リラグルチド - Novo Nordisk)
  • Byetta (エクセナチド - AstraZeneca)
  • Bydureon (エクセナチド - AstraZeneca)

第8章 α-グルコンシダーゼ阻害薬市場

  • 市場実績
  • 収益予測
  • Glucobay (アカルボース - Bayer AG)
  • Basen (ボグリボース - 武田薬品工業)
  • Glyset (ミグリトール - Pfizer)

第9章 メグリチニド市場

  • 市場実績
  • 収益予測
  • Prandin (レパグリニド - Novo Nordisk)
  • Starlix (ナテグリニド - Novartis)
  • Glufast (アカルボース - エーザイ)

第10章 チアゾリジンジオン市場

第11章 SGLT2阻害薬市場

  • 市場実績
  • 収益予測
  • Invokana (カナグリフロジン - Johnson & Johnson)
  • Forxiga (ダパグリフロジン - AstraZeneca)
  • Jardiance (エンパグリフロジン - Eli Lilly)

第12章 ビグアニド市場

  • 市場実績
  • 収益予測
  • Glucophage (メトホルミン - (MSD))
  • Glumetza (塩酸メトホルミン - Salix Pharmaceuticals)
  • Fortamet (塩酸メトホルミン - 塩野義製薬)

第13章 主要国の糖尿病治療薬市場の予測

  • 主要国市場の実績
  • 主要国市場 - 収益予測
  • 米国
  • 日本
  • EU5カ国
  • 中国
  • インド
  • ロシア
  • ブラジル

第14章 糖尿病治療薬市場:開発パイプライン

第15章 世界の糖尿病治療薬市場:SWOT/STEP 分析

第16章 結論

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0218

The global diabetes drugs market was valued at $49.26bn in 2016 and is projected to grow at a CAGR of 6.1% in the first half of the forecast period.to reach global revenue of $66.29bn in 2021. The largest drug class in the market in 2016 was human insulin and analogues. This drug class held 55% share of the global diabetes drugs market in 2016.

How this report will benefit you:

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 262 page report you will receive 75 tables and 141 figures - all unavailable elsewhere.

The 262-page report provides clear detailed insight into the global diabetes drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Diabetes Drugs Market forecasts from 2017-2027
  • Provides qualitative analysis and forecast of the human insulins and analogues submarket for the period 2017-2027:
    • Lantus (insulin aspart)
    • NovoLog (insulin aspart)
    • Humalog (insulin lispro)
    • Levemir (insulin detemir)
    • Human Insulins by Novo Nordisk
    • NovoMix (insulin aspart)
    • Humulin (insulin isophane)
  • Provides qualitative analysis and forecast of the dipeptidyl peptidase-4 inhibitors (DPP-4) submarket for the period 2017-2027:
    • Januvia (sitagliptin)
    • Janumet (sitagliptin and metformin)
    • Galvus (vidagliptin)
    • Onglyza (saxagluiptin)
    • Nesina (alogliptin)
    • Tradjenta (linagliptin)
  • Provides qualitative analysis and forecast of the sulfonylurea submarket for the period 2017-2027:
    • Diamicron (gliclazide)
    • Amaryl (glimepiride)
    • Glucotrol (glipizide)
  • Provides qualitative analysis and forecast of the glucagon-like peptide-1 (GLP-1) receptor agonists submarket for the period 2017-2027:
    • Victoza (liraglutide)
    • Byetta (exenatide)
    • Bydureon (exenatide)
    • Provides qualitative analysis and forecast of the alpha-glucosidase class submarket for the period 2017-2027:
    • Glucobay (acarbose)
    • Basen (voglibose)
    • Glyset (miglitol)
  • Provides qualitative analysis and forecast of the meglitinides submarket for the period 2017-2027:
    • Prandin (repaglinide)
    • Sarlix (nateglinide)
    • Glufast (acarbose).
  • Provides qualitative analysis and forecast of the sodium-glucose co-transporter 2 (SGLT2) inhibitors submarket for the period 2017-2027:
    • Invokana (canagliflozin)
    • Forxiga (dapagliflozin)
    • Jardiance (empaglifozin)
  • Provides qualitative analysis and forecast of the biguanides submarket for the period 2017-2027:
    • Glucophage (metformin)
    • Glumetza (metformin)
    • Fortamet (metformin)
  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • United States
    • Japan
    • EU5 (Germany, France, UK, Italy, Spain)
    • China
    • India
    • Russia
    • Brazil
  • This report discusses the SWOT and STEP Analysis of the global diabetes drugs market
  • This report also discusses the diabetes R&D pipeline, recent approvals and summarizes anti-diabetes drug developments by Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca and others

Visiongain's study is intended for anyone requiring commercial analyses for the global diabetes drugs market. You find data, trends and predictions.

Buy our report today Global Diabetes Drugs Market 2017-2027: Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Introduction to the Diabetes Industry and Market
  • 1.2. Main Report Findings
  • 1.3. This Study Provides the Following Knowledge
  • 1.4. Why You Should Read This Report
  • 1.5. How This Report Delivers
  • 1.6. Main Questions Answered by This Study
  • 1.7. Who is This Study For?
  • 1.8. Research Methods and Analysis
  • 1.9. Frequently Asked Questions (FAQ)
  • 1.10. Associated Visiongain Reports
  • 1.11. About Visiongain

2. Global Diabetes Drugs Market: Introduction

  • 2.1. Global Diabetes Drugs Market Segmentation
  • 2.2. What is Diabetes?
  • 2.3. How is Diabetes Classified?
  • 2.4. Risk Factors, Disease Symptoms and Complications
  • 2.5. Criteria for the Diagnosis of Diabetes
  • 2.6. World and Regional Diabetes Incidence and Prevalence
  • 2.7. The Economic Burden of Diabetes
  • 2.8. Unmet Need
  • 2.9. Leading Classes of Diabetic Medications
    • 2.9.1. Type 1 Medication
      • 2.9.1.1. Insulin
      • 2.9.1.2. Surgical Options
    • 2.9.2. Type 2 Medication
      • 2.9.2.1. Alpha-glucosidase Inhibitors
      • 2.9.2.2. Biguanides
      • 2.9.2.3. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
      • 2.9.2.4. Sodium-Glucose Co-Transporter 2 (SGLT2)
      • 2.9.2.5. Thiazolidinediones
      • 2.9.2.6. Sulfonylureas
      • 2.9.2.7. Meglitinides
      • 2.9.2.8. Other Injectable Medications
      • 2.9.2.9. Combination Drug Therapies for Type 2 Diabetes

3. The World Diabetes Drugs Market, 2017-2027

  • 3.1. The World Diabetes Drug Market, 2016
    • 3.1.1. Diabetes Treatment Market by Drug Class, 2016
    • 3.1.2. Top Selling Diabetes Drugs, 2016
    • 3.1.3. Generic Anti-Diabetes Drugs, 2016
  • 3.2. World Diabetes Drugs Market: Revenue Forecast, 2017-2027
  • 3.3. Injectable and Non-Injectable Diabetes Drugs, 2017-2027
    • 3.3.1. Injectable Diabetes Drugs Revenue Forecast, 2017-2027
    • 3.3.2. Non-Injectable Diabetes Drugs Revenue Forecast, 2017-2027

4. Human Insulin and Analogues, 2017-2027

  • 4.1. Insulin and Insulin Analogues Drugs, 2016
  • 4.2. Insulin and Insulin Analogues: Revenue Forecast, 2017-2027
  • 4.3. Insulin and Insulin Analogues: Market Trends, 2017-2027
    • 4.3.1. Will the Top 3 Insulin Producers Sustain Their Market Dominance?
    • 4.3.2. New Opportunities for Biosimilar Insulin: Is the Era of Biosimilar Insulin Coming?
  • 4.4. Lantus (Insulin Aspart, Novo Nordisk): Revenue Forecast, 2017-2027
  • 4.5. NovoLog (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2017-2027
  • 4.6. Humalog (Insulin Lispro; Eli Lilly): Revenue Forecast, 2017-2027
  • 4.7. Levemir (Insulin Detemir; Novo Nordisk): Revenue Forecast, 2017-2027
  • 4.8. Human Insulins (Novo Nordisk): Revenue Forecast, 2017-2027
  • 4.9. NovoMix (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2017-2027
  • 4.10. Humulin (Insulin Isophane; Eli Lilly): Revenue Forecast, 2017-2027

5. Dipeptidyl Peptidase-4 Inhibitors (DPP-4) Market, 2017-2027

  • 5.1. DPP-4 Market, 2016
  • 5.2. DPP-4 Inhibitors Revenue Forecast, 2017-2027
  • 5.3. Januvia (Sitagliptin; Merck (MSD)): Revenue Forecast, 2017-2027
  • 5.4. Janumet (Sitagliptin and Metaformin; Merck & Co.): Revenue Forecast, 2017-2027
  • 5.5. Galvus (Vildagliptin; Novartis): Revenue Forecast, 2017-2027
  • 5.6. Onglyza (Saxagliptin; AstraZeneca): Revenue Forecast, 2017-2027
  • 5.7. Nesina (Alogliptin; Takeda/Furiex Pharmaceuticals): Revenue Forecast, 2017-2027
  • 5.8. Tradjenta (Linagliptin; Eli Lilly and Boehringer Ingelheim): Revenue Forecast, 2017-2027

6. Sulfonylureas Market, 2017-2027

  • 6.1. Sulfonylureas Market, 2016
  • 6.2. Sulfonylureas: Revenue Forecast 2017-2027
  • 6.3. Sulfonylureas: Market Trends 2017-2027
    • 6.3.1. New Opportunites for Sulfonylureas in Emerging Markets
    • 6.3.2. Side Effects and Competitor Drugs Will Affect Sales
  • 6.4. Diamicron (Gliclazide; Servier): Revenue Forecast, 2017-2027
  • 6.5. Amaryl (Glimepiride; Sanofi): Revenue Forecast, 2017-2027
  • 6.6. Glucotrol XL (Glipizide; Pfizer): Revenue Forecast, 2017-2027

7. Glucagon-Like Peptide-1 (GLP-1) Receptor agonists Market, 2017-2027

  • 7.1. GLP-1 Receptor agonists Market, 2016
  • 7.2. GLP-1 Receptor Agonists Revenue Forecast, 2017-2027
    • 7.2.1. GLP-1 Receptor Agonists: Market Trends, 2017-2027
    • 7.2.2. Promising New Approvals in the GLP-1 Class
    • 7.2.3. GLP-1 Agonists and Weight Loss Results May Boost Revenues
  • 7.3. Victoza (Liraglutide; Novo Nordisk): Revenue Forecast, 2017-2027
  • 7.4. Byetta (Exenatide; AstraZeneca): Revenue Forecast, 2017-2027
  • 7.5. Bydureon (Exenatide; AstraZeneca): Revenue Forecast, 2017-2027

8. Alpha-glucosidase Inhibitors Market, 2017-2027

  • 8.1. Alpha-glucosidase Inhibitors Market, 2016
  • 8.2. Alpha-glucosidase Inhibitors: Revenue Forecast, 2017-2027
    • 8.2.1. Alpha-glucosidase Inhibitors: Market Trends, 2017-2027
      • 8.2.1.1. Decline of Alpha-glucosidase Inhibitors Sales Due to Side Effects
      • 8.2.1.2. Is a New Generation of Alpha-glucosidase Inhibitors Worthwhile?
  • 8.3. Glucobay (Acarbose; Bayer AG): Revenue Forecast, 2017-2027
  • 8.4. Basen (Voglibose; Takeda): Revenue Forecast, 2017-2027
  • 8.5. Glyset (Miglitol; Pfizer): Revenue Forecast, 2017-2027

9. Meglitinides Market, 2017-2027

  • 9.1. Meglitinides Market, 2016
  • 9.2. Meglitinides: Revenue Forecast, 2017-2027
    • 9.2.1. Meglitinides: Market Trends, 2017-2027
      • 9.2.1.1. Combination Therapy: New Future for Meglitinides?
  • 9.3. Prandin (Repaglinide; Novo Nordisk): Revenue Forecast, 2017-2027
  • 9.4. Starlix (Nateglinide; Novartis): Revenue Forecast, 2017-2027
  • 9.5. Glufast (Acarbose; Eisai): Revenue Forecast, 2017-2027

10. Thiazolidinediones Market, 2016

11. Sodium - glucose Co-transporter (SGLT2) Inhibitors Market, 2017-2027

  • 11.1. SGLT2 Inhibitors Market, 2016
  • 11.2. SGLT2 Revenue Forecast, 2017-2027
    • 11.2.1. SGLT2 Market Trends, 2017-2027
  • 11.3. Invokana (Canagliflozin; Johnson & Johnson): Revenue Forecast, 2017-2027
  • 11.4. Forxiga (Dapagliflozin; AstraZeneca): Revenue Forecast, 2017-2027
  • 11.5. Jardiance (Empagliflozin; Eli Lilly): Revenue Forecast, 2017-2027

12. Biguanides Market, 2017-2027

  • 12.1. Biguanides Market, 2016
  • 12.2. Biguanides: Revenue Forecast: 2017-2027
    • 12.2.1. Biguanides: Market trends, 2017-2027
    • 12.2.2. Metformin: Delay of Diabetes
    • 12.2.3. Higher Mortality Associated with Combined Metformin and Insulin
  • 12.3. Glucophage (Metformin; Merck (MSD)): Revenue Forecast, 2017-2027
  • 12.4. Glumetza (Metformin Hydrochloride; Salix Pharmaceuticals): Revenue Forecast, 2017-2027
  • 12.5. Fortamet (Metformin; Shionogi & Co): Revenue Forecast, 2017-2027

13. National Markets for Diabetes Drugs, 2017-2027

  • 13.1. Leading National Markets for Diabetes Drugs, 2016
  • 13.2. Leading National Diabetes Drugs Market: Revenue Forecast, 2017-2027
  • 13.3. The US to Sustain its Market Leadership: Revenue Forecast 2017-2027
    • 13.3.1. High Diabetes Prevalence within a Complex Healthcare System
  • 13.4. The Japanese Market, Revenue Forecast, 2017-2027
    • 13.4.1. Sanofi and Takeda Collaborate to Fight Diabetes in Japan
    • 13.4.2. Novel Treatment Options in Japan
  • 13.5. EU5. (Germany, France, UK, Italy, Spain) Market for Diabetes Drugs, 2016
    • 13.5.1. The EU5 (Germany, France, UK, Italy, Spain) Market Revenue Forecasts, 2017-2027
    • 13.5.2. Germany: Disease Treatment Measures Require Improvement - Revenue Forecast, 2017-2027
      • 13.5.2.1. Tough Reimbursement Rules: More Data for Faster Approval?
    • 13.5.3. French National Diabetes Market Revenue Forecast, 2017-2027
      • 13.5.3.1. Great Standard of Care and Regulatory Reforms in France
    • 13.5.4. The UK National Diabetes Market Revenue Forecast, 2017-2027
      • 13.5.4.1. Faster Approvals for New Therapies in the UK
    • 13.5.5. Italian National Diabetes Market Revenue Forecast, 2017-2027
    • 13.5.6. Spanish National Diabetes Market Revenue Forecast, 2017-2027
  • 13.6. China: The World's Largest Diabetic Population - Revenue Forecast, 2017-2027
    • 13.6.1. Presence of Multinational Companies and the Power of Buyers
    • 13.6.2. Disparity in Regional Health Spending
    • 13.6.3. Multi-Billion Dollar Investment to Improve Healthcare
  • 13.7. The Indian Market: Revenue Forecast, 2017-2027
    • 13.7.1. Focus on the Rural Population
  • 13.8. The Russian National Diabetes Market, 2017-2027
    • 13.8.1. High Out of Pocket Costs Reduce Compliance
  • 13.9. Brazil: Improved Access to Care in Rural Areas - Revenue Forecast, 2017-2027
    • 13.9.1. Localised Insulin Production in Brazil
    • 13.9.2. Diabetes Awareness Initiatives Will Increase Market Potential

14. Diabetes Drug Market R&D Pipeline, 2016

  • 14.1. New Diabetes Drugs Approvals and Leading Companies' Developments, 2015-2016
    • 14.1.1. Novo Nordisk
    • 14.1.2. Eli Lilly & Boehringer Ingelheim
    • 14.1.3. AstraZeneca
  • 14.2. Human Insulins and Analogues: New Approvals
    • 14.2.1. Insulin Glargine (Basaglar, Eli Lilly and Boehringer Ingelheim): Receives US Approval After Delays
    • 14.2.2. Insulin Glargine (Toujeo, Sanofi): Will it Replace Lantus?
    • 14.2.3. Afrezza (Sanofi and MannKind): The First Inhaled Insulin Fails to Make an Impact
  • 14.3. Human Insulins and Analogues: Pipeline Developments: New Approvals
    • 14.3.1. Tresiba (Novo Nordisk): Opportunity Revival
    • 14.3.2. MK-1293 (Merck (MSD) and Biogen Idec): Will Provide more Biosimilar Competition for Lantus
    • 14.3.3. NN9924 (Novo Nordisk)
    • 14.3.4. BIOD-123 (Biodel)
  • 14.4. DPP-4 Inhibitors: Pipeline Developments
    • 14.4.1. Zafatek (Trelagliptin Succinate; Takeda and Furiex Pharmaceuticals): Approved in Japan
    • 14.4.2. Omarigliptin (MK-3102; Merck (MSD))
  • 14.5. GLP-1: New Approvals and Pipeline, 2016
    • 14.5.1. Trulicity (Dulaglutide; Eli Lilly): Potential for Blockbuster Status
    • 14.5.2. Semaglutide (NN9535; Novo Nordisk)
    • 14.5.3. Xultophy (IdegLira; Novo Nordisk)
    • 14.5.4. ITCA 650 (Intarcia Theraputics)
  • 14.6. Sodium Glucose Co-Transporter 2: Pipeline Developments, 2016
    • 14.6.1. Sotagliflozin (Lexicon Pharmacuticals)
    • 14.6.2. Apleway (Tofogliflozin; Sanofi/Takeda)
    • 14.6.3. MK8835 (Ertugliflozin; Merck (MSD))
    • 14.6.4. Bexagliflozin (Theracos)
  • 14.7. Other Diabetes Drugs: Pipeline Developments, 2016
    • 14.7.1. DM199 (DiaMedica)
    • 14.7.2. Glucokinase Activators
      • 14.7.2.1. LY2608204 (Eli Lilly and Yabao Pharmaceutical Inc.)

15. Diabetes World Drug Market: SWOT and STEP Analysis

  • 15.1. SWOT Analysis of the Diabetes Drug Market, 2017-2027
  • 15.2. Strengths
    • 15.2.1. Promising Research and Development
    • 15.2.2. Secondary Indications
    • 15.2.3. Biological Drugs are Tougher to copy and Offer Variety
    • 15.2.4. Market Competition
  • 15.3. Weaknesses
    • 15.3.1. Lack of Disease Awareness
    • 15.3.2. Tougher Reimbursement Rules
    • 15.3.3. Increased Risk of Cardiovascular Complications
    • 15.3.4. Rising Cost of Drug Development
  • 15.4. Opportunities
    • 15.4.1. Rising Disease Prevalence
    • 15.4.2. Emerging National Markets Hold Great Potential
    • 15.4.3. Novel Insulin Delivery Methods
    • 15.4.4. New Classes of Anti-Diabetes Drugs
  • 15.5. Threats
    • 15.5.1. Type 1 Diabetes Vaccine
    • 15.5.2. Increased Popularity of Other Therapies
    • 15.5.3. Generic Drugs: Patent Expiries and Rising Competition
    • 15.5.4. Regulatory Barriers - Challenges Getting Drug Approval
  • 15.6. STEP Analysis of the World Diabetes Drugs Market, 2017-2027
    • 15.6.1. Social Developments
    • 15.6.2. Technological Advances
    • 15.6.3. Economic Factors
    • 15.6.4. Political Issues

16. Conclusions from the Research and Analysis

  • 16.1. The Diabetes Market - Trends Shaping Those Treatments
  • 16.2. Outlook of the Worlds Diabetes Drug Industry, 2017-2027
  • 16.3. Insulin Will Continue to Dominate the Market
  • 16.4. National Diabetes Market Outlooks, 2017-2027
  • 16.5. Future Opportunities
  • Appendices
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 2.1: Types of Injectable Insulin, 2016
  • Table 2.2: Oral Drug Classes for Type 2 Diabetes, 2017
  • Table 2.3: Other Injectable Drugs for Type 2 Diabetes, 2016
  • Table 2.4: Combination Drug Therapies for Type 2 Diabetes, 2016
  • Table 3.1: World Diabetes Drugs Market: Revenue ($m) and Market Share (%) by Type of Medication, 2016
  • Table 3.2: World Diabetes Drugs Market: Sales ($m) and Market Share (%) by Drugs Class, 2016
  • Table 3.3: Top 10 Diabetes Drugs Sales ($m), 2016-2027
  • Table 3.4: World Diabetes Drugs Market: Revenue Forecasts ($m) by Drug Class, 2017-2027
  • Table 3.5: Injectable Diabetes Drugs: Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 3.6: Non-Injectable Diabetes Drugs: Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 4.1: Human Insulins and Analogues: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
  • Table 4.2: Leading Human Insulin and Analogue Drugs: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 4.3: Top 3 Insulin Drug Producers: Insulin Portfolio, Sales ($m), and Insulin Submarket Share (%), 2016
  • Table 4.4: Lantus: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.5: NovoLog: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.6: Humalog: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.7: Levemir: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.8: Human Insulin: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.9: NovoMix: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.10: Humulin: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 5.1: DPP-4 Inhibitors: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
  • Table 5.2: Leading DPP-4 Inhibitor Drugs: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 5.3: Januvia: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 5.4: Janumet: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 5.5: Galvus: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 5.6: Onglyza: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 5.7: Nesina: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 5.8: Tradjenta: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 6.1: Sulfonylureas: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
  • Table 6.2: Leading Sulfonylureas Drugs: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 6.3: Diamicron: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 6.4: Amaryl: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 6.5: Glucotrol: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 7.1: GLP-1: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
  • Table 7.2: Leading GLP-1 Receptor Agonists: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 7.3: Victoza: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 7.4: Byetta: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 7.5: Bydureon: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.1: Alpha-glucosidase Inhibitors: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
  • Table 8.2: Leading Alpha-glucosidase Inhibitors: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 8.3: Glucobay: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.4: Basen: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.5: Glyset: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 9.1: Meglitinides: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
  • Table 9.2: Leading Meglitinides: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 9.3: Prandin: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 9.4: Starlix: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 9.5: Glufast: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 10.1: Thiazolidinediones: Revenues ($m), 2016
  • Table 11.1: SGLT2 Inhibitors: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
  • Table 11.2: Leading SGLT2 Inhibitors: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 11.3: Invokana: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 11.4: Forxiga: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 11.5: Jardiance: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 12.1: Biguanides: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
  • Table 12.2: Leading Biguanides: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 12.3: Glucophage: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 12.4: Glumetza: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 12.5: Fortamet: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
  • Table 13.1: The Global Diabetes Drugs Market: Revenues ($m) and Market Shares (%) by Region, 2016
  • Table 13.2: Leading National Diabetes Drugs Markets: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 13.3: The US: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 13.4: The Japan: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 13.5: EU5 (Germany, France, UK, Italy, Spain) Market: Revenue ($m), EU5 Market Share (%) and Global Market Share, 2016
  • Table 13.6: EU5 Diabetes Drugs Markets: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 13.7: Germany: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 13.8: France: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 13.9: The UK: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 13.10: Italy: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 13.11: Spain: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 13.12: China: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 13.13: India: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 13.14: Russia: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 13.15: Brazil: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
  • Table 14.1: FDA Approvals for Anti-Diabetes Drugs, 2015 and 2016

List of Figures

  • Figure 2.1: Diabetes Drugs Market Segmentation Overview, 2016
  • Figure 2.2: Diabetes Drugs Market Segmentation Overview, 2016
  • Figure 2.3: Diabetes Types and Classification, 2016
  • Figure 2.4: Causes of Diabetes, 2016
  • Figure 2.5: Prevalence of Diabetes in Leading Economic Countries, 2017
  • Figure 3.1: World Diabetes Drugs Market: Market Share (%) by Type of Medication, 2016
  • Figure 3.2: World Diabetes Drugs Market: Market Shares (%) by Drug Class, 2016
  • Figure 3.3: Top 10 Diabetes Drugs by Market Share (%), 2016
  • Figure 3.4: World Diabetes Drugs Market: Revenue Forecast ($m), 2017-2027
  • Figure 3.5: World Diabetes Drugs Market: AGR Forecast (%), 2017-2027
  • Figure 3.6: Injectable Diabetes Drugs: Revenue Forecast ($m), 2017-2027
  • Figure 3.7: Injectable Diabetes Drugs: AGR Forecast (%), 2017-2027
  • Figure 3.8: Non-Injectable Diabetes Drugs: Revenue Forecast ($m), 2017-2027
  • Figure 3.9: Non-Injectable Diabetes Drugs: AGR Forecast (%), 2017-2027
  • Figure 4.1: Human Insulins and Analogues: Market Shares (%) for Leading Drugs, 2016
  • Figure 4.2: Insulin and Insulin Analogues Market: Revenue Forecast ($m), 2017-2027
  • Figure 4.3: Insulin and Insulin Analogues Market: AGR Forecast (%), 2017-2027
  • Figure 4.4: Lantus: Drug Revenue Forecast ($m), 2017-2027
  • Figure 4.5: Lantus: AGR Forecast (%), 2017-2027
  • Figure 4.6: NovoLog: Drug Revenue Forecast ($m), 2017-2027
  • Figure 4.7: NovoLog: AGR Forecast (%), 2017-2027
  • Figure 4.8: Humalog: Drug Revenue Forecast ($m), 2017-2027
  • Figure 4.9: Humalog: AGR Forecast (%), 2017-2027
  • Figure 4.10: Levemir: Drug Revenue Forecast ($m), 2017-2027
  • Figure 4.11: Levemir: AGR Forecast (%), 2017-2027
  • Figure 4.12: Human Insulins: Drug Revenue Forecast ($m), 2017-2027
  • Figure 4.13: Human Insulins: AGR Forecast (%), 2017-2027
  • Figure 4.14: NovoMix: Drug Revenue Forecast ($m), 2017-2027
  • Figure 4.15: NovoMix: AGR Forecast (%), 2017-2027
  • Figure 4.16: Humulin: Drug Revenue Forecast ($m), 2017-2027
  • Figure 4.17: Humulin: AGR Forecast (%), 2017-2027
  • Figure 5.1: DPP-4 Inhibitors: Market Shares (%) for Leading Drugs, 2016
  • Figure 5.2: DPP-4 Inhibitors: Sales ($m) for Leading Drugs, 2016
  • Figure 5.3: DPP-4 Inhibitor Drugs Market: Revenue Forecast ($m), 2017-2027
  • Figure 5.4: DPP-4 Inhibitor Drugs Market: AGR Forecast (%), 2017-2027
  • Figure 5.5: Januvia: Drug Revenue Forecast ($m), 2017-2027
  • Figure 5.6: Januvia: AGR Forecast (%), 2017-2027
  • Figure 5.7: Janumet: Drug Revenue Forecast ($m), 2017-2027
  • Figure 5.8: Janumet: AGR Forecast (%), 2017-2027
  • Figure 5.9: Galvus: Drug Revenue Forecast ($m), 2017-2027
  • Figure 5.10: Galvus: AGR Forecast (%), 2017-2027
  • Figure 5.11: Onglyza: Drug Revenue Forecast ($m), 2017-2027
  • Figure 5.12: Onglyza: AGR Forecast (%), 2017-2027
  • Figure 5.13: Nesina: Drug Revenue Forecast ($m), 2017-2027
  • Figure 5.14: Nesina: AGR Forecast (%), 2017-2027
  • Figure 5.15: Tradjenta: Drug Revenue Forecast ($m), 2017-2027
  • Figure 5.16: Tradjenta: AGR Forecast (%), 2017-2027
  • Figure 6.1: Sulfonylureas: Market Shares (%) for Leading Drugs, 2016
  • Figure 6.2: Sulfonylureas: Sales ($m) for Leading Drugs, 2016
  • Figure 6.3: Sulfonylureas: Drug Revenue Forecast ($m), 2017-2027
  • Figure 6.4: Sulfonylureas: AGR Forecast (%), 2017-2027
  • Figure 6.5: Diamicron: Drug Revenue Forecast ($m), 2017-2027
  • Figure 6.6: Diamicron: AGR Forecast (%), 2017-2027
  • Figure 6.7: Amaryl: Drug Revenue Forecast ($m), 2017-2027
  • Figure 6.8: Amaryl: AGR Forecast (%), 2017-2027
  • Figure 6.9: Glucotrol: Drug Revenue Forecast ($m), 2017-2027
  • Figure 6.10: Glucotrol: AGR Forecast (%), 2017-2027
  • Figure 7.1: GLP-1: Market Shares (%) for Leading Drugs, 2016
  • Figure 7.2: GLP-1: Revenue ($m) for Leading Drugs, 2016
  • Figure 7.3: GLP-1 Receptor Agonists: Revenue Forecast ($m), 2017-2027
  • Figure 7.4: GLP-1 Receptor Agonists: AGR Forecast (%), 2017-2027
  • Figure 7.5: Victoza: Drug Revenue Forecast ($m), 2017-2027
  • Figure 7.6: Victoza: AGR Forecast (%), 2017-2027
  • Figure 7.7: Byetta: Drug Revenue Forecast ($m), 2017-2027
  • Figure 7.8: Byetta: AGR Forecast (%), 2017-2027
  • Figure 7.9: Bydureon: Drug Revenue Forecast ($m), 2017-2027
  • Figure 7.10: Bydureon: AGR Forecast (%), 2017-2027
  • Figure 8.1: Alpha-glucosidase Inhibitors: Market Shares (%) for Leading Drugs, 2016
  • Figure 8.2: Alpha-glucosidase Inhibitors: Revenue Sales ($m), 2016
  • Figure 8.3: Alpha-glucosidase Inhibitors: Revenue Forecast ($m), 2017-2027
  • Figure 8.4: Alpha-glucosidase Inhibitors: AGR Forecast (%), 2017-2027
  • Figure 8.5: Glucobay: Drug Revenue Forecast ($m), 2017-2027
  • Figure 8.6: Glucobay: AGR Forecast (%), 2017-2027
  • Figure 8.7: Basen: Drug Revenue Forecast ($m), 2017-2027
  • Figure 8.8: Basen: AGR Forecast (%), 2017-2027
  • Figure 8.9: Glyset: Drug Revenue Forecast ($m), 2017-2027
  • Figure 8.10: Glyset: AGR Forecast (%), 2017-2027
  • Figure 9.1: Meglitinides: Market Shares (%) for Leading Drugs, 2016
  • Figure 9.2: Meglitinides: Market Sales ($m) for Leading Drugs, 2016
  • Figure 9.3: Meglitinides: Revenue Forecast ($m), 2017-2027
  • Figure 9.4: Meglitinides: AGR Forecast (%), 2017-2027
  • Figure 9.5: Prandin: Drug Revenue Forecast ($m), 2017-2027
  • Figure 9.6: Prandin: AGR Forecast (%), 2017-2027
  • Figure 9.7: Starlix: Drug Revenue Forecast ($m), 2017-2027
  • Figure 9.8: Starlix: AGR Forecast (%), 2017-2027
  • Figure 9.9: Glufast: Drug Revenue Forecast ($m), 2017-2027
  • Figure 9.10: Glufast: AGR Forecast (%), 2017-2027
  • Figure 10.1: Thiazolidinediones: Revenues ($m), 2016
  • Figure 11.1: SGLT2 Inhibitors: Market Share (%) for Leading Drugs, 2016
  • Figure 11.2: SGLT2 Inhibitors: Sales ($m) for Leading Drugs, 2016
  • Figure 11.3: SGLT2 Inhibitors: Revenue Forecast ($m), 2017-2027
  • Figure 11.4: SGLT2 Inhibitors: AGR Forecast (%), 2017-2027
  • Figure 11.5: Invokana: Drug Revenue Forecast ($m), 2017-2027
  • Figure 11.6: Invokana: AGR Forecast (%), 2017-2027
  • Figure 11.7: Forxiga: Drug Revenue Forecast ($m), 2017-2027
  • Figure 11.8: Forxiga: AGR Forecast (%), 2017-2027
  • Figure 11.9: Jardiance: Drug Revenue Forecast ($m), 2017-2027
  • Figure 11.10: Jardiance: AGR Forecast (%), 2017-2027
  • Figure 12.1: Biguanides: Market Shares (%) for Leading Drugs, 2016
  • Figure 12.2: Biguanides: Revenue ($m) for Leading Drugs, 2016
  • Figure 12.3: Biguanides: Revenue Forecast ($m), 2017-2027
  • Figure 12.4: Biguanides: AGR Forecast (%), 2017-2027
  • Figure 12.5: Glucophage: Drug Revenue Forecast ($m), 2017-2027
  • Figure 12.6: Glucophage: AGR Forecast (%), 2017-2027
  • Figure 12.7: Glumetza: Drug Revenue Forecast ($m), 2017-2027
  • Figure 12.8: Glumetza: AGR Forecast (%), 2017-2027
  • Figure 12.9: Fortamet: Drug Revenue Forecast ($m), 2017-2027
  • Figure 12.10: Fortamet: AGR Forecast (%), 2017-2027
  • Figure 13.1: The Global Diabetes Drugs Market: Revenues ($m) by Region, 2016
  • Figure 13.2: The Global Diabetes Drugs Market: Market Shares (%) by Region, 2016
  • Figure 13.3: The US Diabetes Drugs Market: Revenue Forecast ($m), 2017-2027
  • Figure 13.4: The US Diabetes Drugs Market: AGR Forecast (%), 2017-2027
  • Figure 13.5: The Japanese Diabetes Drugs Market: Revenue Forecast ($m), 2017-2027
  • Figure 13.6: The Japanese Diabetes Drugs Market: AGR Forecast (%), 2017-2027
  • Figure 13.7: The EU5 (Germany, France, UK, Italy, Spain) Countries: Revenue ($m) by Country, 2016
  • Figure 13.8: EU5 (Germany, France, UK, Italy, Spain) Countries: EU5 Market Shares (%) by Country, 2016
  • Figure 13.9: EU5 (Germany, France, UK, Italy, Spain): Revenue Forecast ($m), 2017-2027
  • Figure 13.10: EU5 (Germany, France, UK, Italy, Spain): AGR Forecast (%), 2017-2027
  • Figure 13.11: EU5 (Germany, France, UK, Italy, Spain): Revenue Forecasts by Country ($m), 2017-2027
  • Figure 13.12: Germany: Revenue Forecast ($m), 2017-2027
  • Figure 13.13: Germany: AGR Forecast (%), 2017-2027
  • Figure 13.14: France: Revenue Forecast ($m), 2017-2027
  • Figure 13.15: France: AGR Forecast (%), 2017-2027
  • Figure 13.16: UK: Revenue Forecast ($m), 2017-2027
  • Figure 13.17: UK: AGR Forecast (%), 2017-2027
  • Figure 13.18: Italy: Revenue Forecast ($m), 2017-2027
  • Figure 13.19: Italy: AGR Forecast (%), 2017-2027
  • Figure 13.20: Spain: Revenue Forecast ($m), 2017-2027
  • Figure 13.21: Spain: AGR Forecast (%), 2017-2027
  • Figure 13.22: China: Revenue Forecast ($m), 2017-2027
  • Figure 13.23: China: AGR Forecast (%), 2017-2027
  • Figure 13.24: India: Revenue Forecast ($m), 2017-2027
  • Figure 13.25: India: AGR Forecast (%), 2017-2027
  • Figure 13.26: Russia: Revenue Forecast ($m), 2017-2027
  • Figure 13.27: Russia: AGR Forecast (%), 2017-2027
  • Figure 13.28: Brazil: Revenue Forecast ($m), 2017-2027
  • Figure 13.29: Brazil: AGR Forecast (%), 2017-2027
  • Figure 15.1: SWOT Analysis of the World Diabetes Drugs Market, 2017-2027
  • Figure 15.2: STEP Analysis of the World Diabetes Drugs Market, 2017-2027
  • Figure 17.1: Revenue for the Main Diabetes Drugs Classes ($m), 2016, 2021 and 2027
  • Figure 17.2: Revenue for the Main National Diabetes Markets ($m), 2016, 2021 and 2027

Companies Listed

  • Actavis
  • Alphapharm
  • Amylin Pharmaceuticals (acquired by Bristol Myers Squibb)
  • Andromeda Biotech
  • Arisaph
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Biocon
  • Blue Cross
  • Bristol-Myers Squibb
  • Biogen Idec
  • Boehringer Ingelheim
  • Boston Therapeutics
  • Chugai Pharmaceutical
  • Diabetes UK
  • DiaMedica
  • Diamyd Medical
  • Eisai
  • Eli Lilly
  • Express Scripts
  • Franco-Indian Pharmaceuticals
  • Furiex Pharmaceuticals
  • Genentech
  • Generex Biotechnology Corporation
  • GlaxoSmithKline (GSK)
  • Glenmark Pharmaceuticals
  • Google
  • Human Genome Sciences
  • Intarcia
  • Janssen (subsidiary of J&J)
  • Johnson & Johnson (J&J)
  • Lupin
  • Kissei Pharmaceuticals
  • Kotobuki Pharma
  • Kowa
  • MannKind Corporation
  • Mascot Health Series
  • Merck & Co.
  • Merck Serono
  • MSD KK (Asian subsidiary of Merck & Co.)
  • Mylan
  • Novartis
  • Novo Nordisk
  • Ono Pharmaceuticals
  • Oramed Pharmaceuticals
  • Patheon
  • Pfizer
  • Ranbaxy Laboratories
  • Roche
  • Salix Pharmaceuticals
  • Sandoz
  • Sanofi
  • Santarus (bought by Salix Pharmaceuticals)
  • Servier
  • Shantha Biotechnics (acquired by Sanofi)
  • Shionogi Pharmaceuticals
  • Shreya Life Sciences
  • Sun Pharma
  • Takeda
  • Taisho Pharmaceutical
  • Teva Pharmaceutical Industries
  • Theracos
  • Transdermal Specialities
  • Yabao Pharmaceutical
  • Zydus Cadila

Organizations Mentioned in the Report:

  • American Diabetes Association
  • Associacao Nacional de Assistencia ao Diabetico (ANAD, Brazil)
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • International Diabetes Federation (IDF)
  • Ministry of Health (MoH, Germany)
  • Ministry of Health, Labour and Welfare (MHLW, Japan)
  • National Health Service (NHS, UK)
  • National Institute of Health and Clinical Excellence (NICE, UK)
  • Stanford University School of Medicine
  • World Health Organization (WHO)
Back to Top